Back to top

Image: Bigstock

Alcon (ALC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Read MoreHide Full Article

Alcon (ALC - Free Report) reported $2.78 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 8%. EPS of $0.84 for the same period compares to $0.76 a year ago.

The reported revenue represents a surprise of +0.58% over the Zacks Consensus Estimate of $2.77 billion. With the consensus EPS estimate being $0.77, the EPS surprise was +9.09%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Net Sales and other revenues- Net Sales: $2.78 billion versus $2.76 billion estimated by three analysts on average.
  • Net Sales- Total Surgical: $1.57 billion versus the three-analyst average estimate of $1.55 billion. The reported number represents a year-over-year change of +7.9%.
  • Net Sales- Total Vision care: $1.21 billion versus $1.21 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8% change.
  • Net Sales- Total Surgical- Consumables: $825 million versus $822.67 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.2% change.
  • Net Sales and other revenues- Other revenues: $41 million versus $18.82 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +115.8% change.
  • Net Sales- Total Vision Care- Contact lenses: $726 million versus $726.96 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.
  • Net Sales- Total Vision Care- Ocular health: $486 million versus the three-analyst average estimate of $479.63 million. The reported number represents a year-over-year change of +13%.
  • Net Sales- Total Surgical- Implantables: $466 million versus $463.72 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.2% change.
  • Net Sales- Total Surgical- Equipment/other: $279 million versus $266.86 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +25.7% change.

View all Key Company Metrics for Alcon here>>>

Shares of Alcon have returned +5.9% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Published in